[Form 4] Health In Tech, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Health In Tech, Inc. (HIT) reported an insider grant to Tim Johnson, who is the company's Chief Executive Officer, a director and a >10% owner. On 09/24/2025 Mr. Johnson was granted 80,000 restricted shares of Class A Common Stock under the Health in Tech Equity Incentive Plan at no cash price. The restricted shares vest in three equal tranches, each vesting monthly over a 12-month period tied to milestones: signing a letter of intent or MOU for an initiative, proof-of-concept or beta launch, and full commercial launch. After the grant Mr. Johnson beneficially owns 22,549,741 shares (which the form notes includes 137,495 restricted shares and 22,412,246 Class A shares); the filing excludes 9,000,000 Class B shares and 734,707 options.

Positive

• 80,000 restricted Class A shares were granted to CEO Tim Johnson, providing equity-based alignment with company performance
• Vesting tied to specific milestones (LOI/MOU, proof-of-concept/beta, full commercial launch), aligning incentives with operational progress
• Clear disclosure of post-grant beneficial ownership and exclusions (restricted shares, Class B, and options) on Form 4

Negative

• None.

Insights

Financial Analyst

TL;DR: CEO received 80,000 restricted Class A shares with milestone-based vesting, increasing reported beneficial ownership to 22.55M shares.

The grant represents a non-cash, equity-based compensation event recorded on Form 4 for timeliness and disclosure. Vesting is tied to specific operational milestones rather than time alone, aligning payoff with commercial progress. The post-grant beneficial ownership figure reported includes restricted shares and outstanding Class A shares but explicitly excludes substantial Class B holdings and outstanding options, which are material to control and potential dilution analyses. This transaction is routine for executive compensation and informative for ownership tracking.

Corporate Governance Expert

TL;DR: Milestone-linked restricted-stock grant to CEO signals incentive alignment with company initiatives and requires continued disclosure as milestones progress.

The Form 4 discloses the grant structure and vesting triggers clearly, which is good governance practice for transparency. The filing confirms Mr. Johnson's roles as CEO and director and reports his beneficial ownership after the grant. The form also transparently notes exclusions (Class B shares and options) from the reported Class A total, which stakeholders should consider when assessing voting control and future dilution. No amendment or sale activity is reported.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Johnson Tim Donald

(Last) (First) (Middle)

701 S. COLORADO AVE,

SUITE 1

(Street)

STUART FL 34994

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Health In Tech, Inc. [ HIT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	09/24/2025		A		80,000(1)	A	$0	22,549,741(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted shares of Class A Common Stock granted to the reporting person pursuant to the Health in Tech Equity Incentive Plan. One third (1/3) of the shares of restricted stock granted to the reporting person shall vest in equal monthly installments over a twelve (12) month period commencing on the date a letter of intent or memorandum of understanding is signed in connection with an initiative being developed by the Company (the "Initiative"), one third (1/3) of the shares shall vest in equal monthly installments over a twelve (12) month period commencing on the date the Initiative enters proof-of-concept or beta launch, and, the remaining one third (1/3) of the shares shall vest in equal monthly installments over a twelve (12) month period commencing on the date of full commercial launch of the Initiative.

2. Includes 137,495 shares of restricted stock and 22,412,246 shares of Class A Common Stock. Excludes 9,000,000 shares of Class B Common Stock and 734,707 options to purchase shares of Class A Common Stock.

	/s/ Tim Johnson	09/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Tim Johnson report on Form 4 for HIT?

The Form 4 reports a grant of 80,000 restricted Class A Common Stock to Tim Johnson on 09/24/2025 under the company's equity incentive plan.

How do the restricted shares vest for the 80,000-share grant?

Vesting occurs in three equal groups: one-third vests monthly over 12 months after a signed LOI/MOU for an initiative, one-third vests monthly over 12 months after proof-of-concept/beta launch, and one-third vests monthly over 12 months after full commercial launch.

What is Tim Johnson's reported beneficial ownership after the transaction?

After the reported transaction Mr. Johnson beneficially owns 22,549,741 shares (which includes 137,495 restricted shares and 22,412,246 Class A shares), per the filing.

Does the Form 4 disclose other equity interests excluded from the Class A total?

Yes. The filing states it excludes 9,000,000 Class B shares and 734,707 options to purchase Class A Common Stock from the reported Class A total.

What roles does Tim Johnson hold at Health In Tech according to the filing?

The Form 4 lists Tim Johnson as Chief Executive Officer, a director, and a >10% owner of the issuer.